Nanordica® Advanced Antibacterial Wound Dressing
Diabetic Foot Ulcers (DFU)
Key Facts
About Nanordica Medical
Nanordica Medical is a private, clinical-stage medtech company spun out from Estonia's National Institute of Chemical Physics and Biophysics. The company has developed a novel wound dressing based on silk nanofibers and synergistic antibacterial nanoparticles (Premotiv® technology), designed to address the high unmet need in chronic wound care, particularly diabetic foot ulcers. It has achieved ISO 13485:2016 certification and is conducting a large-scale, multi-center clinical trial to validate its product's efficacy against the standard of care. The company raised €1.75M in 2024 to advance its clinical and commercial efforts.
View full company profileAbout Nanordica Medical
Nanordica Medical is a private, clinical-stage medtech company spun out from Estonia's National Institute of Chemical Physics and Biophysics. The company has developed a novel wound dressing based on silk nanofibers and synergistic antibacterial nanoparticles (Premotiv® technology), designed to address the high unmet need in chronic wound care, particularly diabetic foot ulcers. It has achieved ISO 13485:2016 certification and is conducting a large-scale, multi-center clinical trial to validate its product's efficacy against the standard of care. The company raised €1.75M in 2024 to advance its clinical and commercial efforts.
View full company profileTherapeutic Areas
Other Diabetic Foot Ulcers (DFU) Drugs
| Drug | Company | Phase |
|---|---|---|
| Intralesional rhEGF (Heberprot-P related) | Discovery Therapeutics Caribe | Phase 3 |
| DeepView Wound Imaging System | Spectral AI | Unknown |
| ORBCEL™ for Diabetic Foot Ulcers | Orbsen Therapeutics | Pre-clinical/Research |
| ABCB5+ MSCs | RHEACELL | Pre-clinical development |